{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:38:46Z","timestamp":1793363926291,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20575"],"award-info":[{"award-number":["20575"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41375-021-01193-6","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T07:04:32Z","timestamp":1614755072000},"page":"2672-2683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3234","authenticated-orcid":false,"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guidetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-2554","authenticated-orcid":false,"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-4808","authenticated-orcid":false,"given":"Jean Marc Schiano","family":"De Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Spilleboudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Dahncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Serritella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"Remy","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Moles-Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Romancik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4265","authenticated-orcid":false,"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatcher J.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1603","authenticated-orcid":false,"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"issue":"Oct","key":"1193_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P. et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(Oct):1144\u201353.","journal-title":"Blood"},{"issue":"May","key":"1193_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(May):1428\u201339. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29584546","journal-title":"J Clin Oncol"},{"issue":"Apr","key":"1193_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/bmt.2015.332","volume":"51","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transpl. 2016;51(Apr):521\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26726948","journal-title":"Bone Marrow Transpl"},{"issue":"Mar","key":"1193_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales M-A. et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood. 2017;129(Mar):1380\u20138.","journal-title":"Blood"},{"key":"1193_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","volume":"22","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist. 2017;22:585\u201391. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28438889","journal-title":"Oncologist"},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25:94\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30195074","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Sep","key":"1193_CR7","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","volume":"2","author":"LK Schoch","year":"2018","unstructured":"Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P. et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018;2(Sep):2226\u20139.","journal-title":"Blood Adv"},{"issue":"Nov","key":"1193_CR8","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.3324\/haematol.2019.215962","volume":"104","author":"B Casadei","year":"2019","unstructured":"Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, et al. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma patients: a retrospective single center case series. Haematologica. 2019;104(Nov):e521\u20132. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30890595","journal-title":"Haematologica"},{"issue":"Apr","key":"1193_CR9","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","volume":"4","author":"C De Philippis","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, Montes de Oca C, Dul\u00e9ry R, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(Apr):1242\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32227210","journal-title":"Blood Adv"},{"key":"1193_CR10","doi-asserted-by":"crossref","unstructured":"Paul S, Zahurak M, Luznik L, Ambinder RF, Fuchs EJ, Bola\u00f1os-Meade J, et al. Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study. Biol Blood Marrow Transpl. 2020. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32592857. Accessed 13 Jul 2020","DOI":"10.1016\/j.bbmt.2020.06.012"},{"issue":"Jul","key":"1193_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","volume":"132","author":"C Herbaux","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018;132(Jul):9\u201316. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29720488","journal-title":"Blood"},{"issue":"Sep","key":"1193_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(Sep):3059\u201367. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25113753","journal-title":"J Clin Oncol"},{"key":"1193_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4329079\/","journal-title":"Biol Blood Marrow Transpl"},{"key":"1193_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1193_CR15","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140\u201354.","DOI":"10.1214\/aos\/1176350951"},{"issue":"Jun","key":"1193_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(Jun):496\u2013509. http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"issue":"Sep","key":"1193_CR17","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","volume":"25","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide\u2013based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25(Sep):1859\u201368. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31132455","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Oct","key":"1193_CR18","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"C Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the European society for blood and marrow transplantation. J Clin Oncol. 2017;35(Oct):3425\u201332. http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.72.6869","journal-title":"J Clin Oncol"},{"issue":"Jan","key":"1193_CR19","first-page":"143","volume":"44","author":"D Michonneau","year":"2016","unstructured":"Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P. The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation. Immunology. 2016;44(Jan):143\u201354. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26795248","journal-title":"Immunology"},{"issue":"Oct","key":"1193_CR20","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","volume":"122","author":"A Saha","year":"2013","unstructured":"Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(Oct):3062\u201373. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3811178&tool=pmcentrez&rendertype=abstract","journal-title":"Blood"},{"issue":"Aug","key":"1193_CR21","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","volume":"171","author":"BR Blazar","year":"2003","unstructured":"Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(Aug):1272\u20137. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12874215","journal-title":"J Immunol"},{"issue":"Dec","key":"1193_CR22","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","volume":"3","author":"S Ikegawa","year":"2019","unstructured":"Ikegawa S, Meguri Y, Kondo T, Sugiura H, Sando Y, Nakamura M. et al. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade. Blood Adv. 2019;3(Dec):4081\u201394.","journal-title":"Blood Adv"},{"key":"1193_CR23","unstructured":"Nieto JC, Rold\u00e1n E, Jim\u00e9nez I, Fox L, Carabia J, Ort\u00ed G, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020; http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32393842. Accessed 27 Jul 2020 ."},{"issue":"Oct","key":"1193_CR24","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, et al. Severe cytokine-release syndrome after T cell\u2013replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti\u2013IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transpl. 2016;22(Oct):1851\u201360. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116301458","journal-title":"Biol Blood Marrow Transpl"},{"key":"1193_CR25","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Investig. 2019;129:2357\u201373. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30913039","journal-title":"J Clin Investig"},{"issue":"May","key":"1193_CR26","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.32796","volume":"126","author":"B Oran","year":"2020","unstructured":"Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors. Cancer. 2020;126(May):2193\u2013205. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32125707","journal-title":"Cancer"},{"issue":"Jun","key":"1193_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00277-020-04033-2","volume":"99","author":"I Pasic","year":"2020","unstructured":"Pasic I, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W. et al. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2020;99(Jun):1377\u201387.","journal-title":"Ann Hematol"},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clml.2020.04.003","volume":"20","author":"J El-Cheikh","year":"2020","unstructured":"El-Cheikh J, Devillier R, Dulery R, Massoud R, Al Chami F, Ghaoui N, et al. Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation. Clin Lymphoma Myeloma Leuk 2020;20:617\u201323.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1193_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transpl. 2018;24:627\u201332. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29197681","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01193-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T21:05:54Z","timestamp":1671483954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01193-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01193-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RWM, LC, LG, VTH, PC, AG, BC, MAS, SA, RL, JMSdC, DB, LD, AKS, TB, GS, CS, SMA, AVS, M-PM-M, CO, KB, LL, A Beitinjaneh, UR, MM, RD, SN, TP, RMJ, MR, A Bashey, HJB, JTR, VT, MS, CdP, and MM\u2014none. DAB\u2014Honoraria: Seattle Genetics. SJ\u2014Honoraria: Novartis, Kite, Juno, Takeda, CRISPR Therapeutics. GLS\u2014Research funding: Janssen, Amgen. M-AP\u2014honoraria from Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite\/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Cidara Therapeutics, Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite\/Gilead, and Miltenyi Biotec. He serves in a volunteer capacity as a member of the Board of Directors of Be The Match (National Marrow Donor Program, NMDP), as well as on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Executive Committee. AFH\u2014Research funding: BMS, Merck, Genentech, Inc.\/F. Hoffmann-La Roche Ltd., Gilead Sciences, Seattle Genetics, Immune Design, AstraZeneca, Pharmacyclics. Consultancy: BMS, Merck, Genentech, Inc.\/F. Hoffmann-La Roche Ltd., Gilead Sciences, Seattle Genetics, Karyopharm. Travel, Accommodation, Expenses: BMS. YN\u2014Consultant: Affimed. Research funds: Astra Zeneca, Affimed, Novartis, Secura Bio. MH\u2014Research Support\/Funding: Takeda Pharmaceutical Company; Astellas Pharma. Consultancy: Incyte Corporation; ADC Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio. Speaker\u2019s Bureau: Sanofi Genzyme, AstraZeneca. TAF\u2014Consultant.\/Ad Board: Seattle Genetics\/BMS\/Celgene\/Karyopharm\/KITE. Honoraria: Takeda\/Celgene\/Seattle Genetics\/AbbVie\/Pharmacyclics\/Janssen\/KITE\/BMS. Speaker Bureau: Takeda\/Celgene\/Seattle Genetics\/AbbVie\/Pharmacyclics\/Janssen\/KITE\/BMS. JPM\u2014Research funding from Novartis, Fresenius Biotech, Astellas, Bellicum Pharmaceuticals, Gamida Cell, Kite Pharmaceuticals, Pluristem Ltd., Juno Therapeutics, and AlloVir. Advisory board and travel accommodations\/expenses from Kite Pharmaceuticals, Juno Therapeutics AlloVir. Honoraria from Kite Pharmaceuticals and AlloVir. TN\u2014Research funding: Novartis and Karypharm. JC\u2014Personal fees: Kite\/Gilead, Novartis, Morphosys, Bayer, Epyzime, AstraZeneca, Genentech, Karyopharm, Celgene\/Juno. Research Support: Merck. JK\u2014Research funding: Merck. AS\u2014Honoraria: Celgene. Consultancy: Takeda. Other: Pfizer. RH\u2014Honoraria: BMS, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. GM\u2014Honoraria: Bristol Myers Squibb. DM\u2014Editorial board: MorphoSys. RR\u2014Research funding: Merck. Consultancy\/Advisory: BMS. MJF\u2014Consultancy\/Advisory board: Novartis, Kite\/Gilead, Celgene\/BMS, and Arcellx. Y-BC\u2014Consulting: Magenta, Incyte, Abbvie, Daiichi, Equilium, Actinium, Takeda. RCL\u2014Research funding: Juno Therapeutics, Takeda, TG Therapeutics, Incyte, Rhizen Pharmaceuticals, Bayer, Cyteir, Genentech. Consultancy: MorphoSys. SDS\u2014Research funding: Acerta Pharma BV, Astrazeneca, Bayer, Beigene, Ayala, Bristol Myers Squibb, De Novo Biopharma, Genentech, Ignyta, Incyte Corporation, Merck, Sharp and Dohme Corp., Pharmacyclics, Portola Pharmaceuticals, Seattle Genetics. Consultancy or Advisory Board: Astrazeneca, Millenium\/Takeda, Beigene, Karyopharm, KITE pharma. MTB\u2014Research funding: Karyopahrm. Consulting: Concert, Celgene\/Celularity. JBC\u2014Research funding: BMS\/Celgene. JS\u2014Consultancy: Adaptive, AstraZeneca, Atara, BMS, Genmab, Imbrium, Pharmacyclics, and Seattle Genetics. Research Funding: AstraZeneca, BMS, Incyte, Merck, Pharmacyclics, Seattle Genetics, and TG. AS\u2014Advisory Board: BMS, Servier, Gilead, Pfizer, Eisai, Bayer, MSD. Consultancy: Arqule, Sanofi. Speaker\u2019s Bureau: Takeda, BMS, Roche, Abbvie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD. PA\u2014Consultancy: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome. Research funding (inst): Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, IGM, Kite. Honoraria: Merck, BMS. PLZ\u2014Consultancy: Verastem, MSD, Eusapharma, Sanofi. Speaker\u2019s Bureau: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, Immune Design, Celgene, Portola, Roche, Eusapharma, Kyowa Kirin. Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, Immune Design, Celgene, Portola, Roche, Eusapharma, Kyowa Kirin, Sanofi. CC-S\u2014Consultancy: Servier, ADC Therapeutics, Roche, Sanofi, BMS, Merck, Karyopharm. Honoraria: Janssen Oncology AstraZeneca. Research support: ADC Therapeutics, Rhizen Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}